Anna Halama1, Hassan Kahal2, Aditya M Bhagwat1, Jonas Zierer3, Thozhukat Sathyapalan2, Johannes Graumann4,5, Karsten Suhre1, Stephen L Atkin1. 1. Department of Physiology and Biophysics, Weill Cornell Medicine Qatar, Education City, Doha, Qatar. 2. Academic Endocrinology, Diabetes and Metabolism, Hull York Medical School, Hull, UK. 3. Caryl and Israel Englander Institute for Precision Medicine, Institute for Computational Biomedicine, Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, New York. 4. Proteomics Core, Weill Cornell Medicine-Qatar, Education City, Doha, Qatar. 5. Scientific Service Group Biomolecular Mass Spectrometry, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany.
Abstract
AIMS: To determine the biochemical changes that underlie hypoglycaemia in a healthy control group and in people with type 2 diabetes (T2D). MATERIALS AND METHODS: We report a hypoglycaemic clamp study in seven healthy controls and 10 people with T2D. Blood was withdrawn at four time points: at baseline after an overnight fast; after clamping to euglycaemia at 5 mmol/L; after clamping to hypoglycaemia at 2.8 mmol/L; and 24 hours later, after overnight fast. Deep molecular phenotyping using non-targeted metabolomics and the SomaLogic aptamer-based proteomics platform was performed on collected samples. RESULTS: A total of 955 metabolites and 1125 proteins were identified, with significant alterations in >90 molecules. A number of metabolites significantly increased during hypoglycaemia, but only cortisol, adenosine-3',5'-cyclic monophosphate (cyclic AMP), and pregnenolone sulphate, were independent of insulin. By contrast, identified protein changes were triggered by hypoglycaemia rather than insulin. The T2D group had significantly higher levels of fatty acids including 10-nonadecenoate, linolenate and dihomo-linoleate during hypoglycaemia compared with the control group. Molecules contributing to cardiovascular complications such as fatty-acid-binding protein-3 and pregnenolone sulphate were altered in the participants with T2D during hypoglycaemia. Almost all molecules returned to baseline at 24 hours. CONCLUSIONS: The present study provides a comprehensive description of molecular events that are triggered by insulin-induced hypoglycaemia. We identified deregulated pathways in T2D that may play a role in the pathophysiology of hypoglycaemia-induced cardiovascular complications.
AIMS: To determine the biochemical changes that underlie hypoglycaemia in a healthy control group and in people with type 2 diabetes (T2D). MATERIALS AND METHODS: We report a hypoglycaemic clamp study in seven healthy controls and 10 people with T2D. Blood was withdrawn at four time points: at baseline after an overnight fast; after clamping to euglycaemia at 5 mmol/L; after clamping to hypoglycaemia at 2.8 mmol/L; and 24 hours later, after overnight fast. Deep molecular phenotyping using non-targeted metabolomics and the SomaLogic aptamer-based proteomics platform was performed on collected samples. RESULTS: A total of 955 metabolites and 1125 proteins were identified, with significant alterations in >90 molecules. A number of metabolites significantly increased during hypoglycaemia, but only cortisol, adenosine-3',5'-cyclic monophosphate (cyclic AMP), and pregnenolone sulphate, were independent of insulin. By contrast, identified protein changes were triggered by hypoglycaemia rather than insulin. The T2D group had significantly higher levels of fatty acids including 10-nonadecenoate, linolenate and dihomo-linoleate during hypoglycaemia compared with the control group. Molecules contributing to cardiovascular complications such as fatty-acid-binding protein-3 and pregnenolone sulphate were altered in the participants with T2D during hypoglycaemia. Almost all molecules returned to baseline at 24 hours. CONCLUSIONS: The present study provides a comprehensive description of molecular events that are triggered by insulin-induced hypoglycaemia. We identified deregulated pathways in T2D that may play a role in the pathophysiology of hypoglycaemia-induced cardiovascular complications.
Authors: Wang Lijing; Ke Sujie; Wang Linxi; Huang Lishan; Qi Liqin; Zhan Zhidong; Wu Kejun; Zhang Mengjun; Liu Xiaoying; Liu Xiaohong; Liu Libin Journal: Front Endocrinol (Lausanne) Date: 2022-06-17 Impact factor: 6.055
Authors: Abu Saleh Md Moin; Manjula Nandakumar; Hassan Kahal; Thozhukat Sathyapalan; Stephen L Atkin; Alexandra E Butler Journal: Cells Date: 2021-11-10 Impact factor: 6.600
Authors: Manjunath Ramanjaneya; Ruth Priyanka; Milin Bensila; Jayakumar Jerobin; Krunal Pawar; Thozhukat Sathyapalan; Abdul Badi Abou-Samra; Najeeb M Halabi; Abu Saleh Md Moin; Stephen L Atkin; Alexandra E Butler Journal: Front Endocrinol (Lausanne) Date: 2022-08-09 Impact factor: 6.055
Authors: Abu Saleh Md Moin; Thozhukat Sathyapalan; Stephen L Atkin; Alexandra E Butler Journal: Cardiovasc Diabetol Date: 2022-10-06 Impact factor: 8.949
Authors: Anna Halama; Noor N Suleiman; Michal Kulinski; Ilham Bettahi; Shaimaa Hassoun; Meis Alkasem; Ibrahem Abdalhakam; Ahmad Iskandarani; Tareq A Samra; Stephen L Atkin; Karsten Suhre; Abdul Badi Abou-Samra Journal: Sci Rep Date: 2020-10-13 Impact factor: 4.379